Smoking cessation can be achieved with or without assistance from healthcare professionals, or the use of medications. However, a combination of personal efforts and medications proves more effective to many smokers. Methods that have been found to be effective include interventions directed at or via health care providers and health care systems; medications including nicotine replacement therapy (NRT) and varenicline; individual and group counselling; and Web-based or stand-alone and computer programs. Although stopping smoking can cause short-term side effects such as reversible weight gain, smoking cessation services and activities are cost-effective because of the positive health benefits.
In a growing number of countries, there are more ex-smokers than smokers.
Early "failure" is a normal part of trying to stop, and more than one attempt at stopping smoking prior to longer-term success is common.
NRT, other prescribed pharmaceuticals, and professional counselling or support also help many smokers.
However, up to three-quarters of ex-smokers report having quit without assistance ("cold turkey" or cut down then quit), and cessation without professional support or medication may be the most common method used by ex-smokers.
Major reviews of the scientific literature on smoking cessation include:
Systematic reviews of the Cochrane Tobacco Addiction Group of the Cochrane Collaboration. As of 2012, this independent, international, not-for-profit organization has published over 60 systematic reviews "on interventions to prevent and treat tobacco addiction" which will be referred to as "Cochrane reviews."
Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update of the United States Department of Health and Human Services, which will be referred to as the "2008 Guideline." The Guideline was originally published in 1996 and revised in 2000. For the 2008 Guideline, experts screened over 8700 research articles published between 1975 and 2007.:13–14 More than 300 studies were used in meta-analyses of relevant treatments; an additional 600 reports were not included in meta-analyses, but helped formulate the recommendations.:22 Limitations of the 2008 Guideline include its not evaluating studies of "cold turkey" methods ("unaided quit attempts") and its focus on studies that followed up subjects only to about 6 months after the "quit date" (even though almost one-third of former smokers who relapse before one year will do so 7–12 months after the "quit date").:19,23
As it is common for ex-smokers to have made a number of attempts (often using different approaches on each occasion) to stop smoking before achieving long-term abstinence, identifying which approach or technique is eventually most successful is difficult; it has been estimated, for example, that "only about 4% to 7% of people are able to quit smoking on any given attempt without medicines or other help.". However, in analysing a 1986 U.S. survey, Fiore et al. (1990) found that 95% of former smokers who had been abstinent for 1–10 years had made an unassisted last quit attempt. The most frequent unassisted methods were "cold turkey" and "gradually decreased number" of cigarettes. A 1995 meta-analysis estimated that the quit rate from unaided methods was 7.3% after an average of 10 months of follow-up.
"Cold turkey" is a colloquial term indicating abrupt withdrawal from an addictive drug, and in this context indicates sudden and complete cessation of all nicotine use. In three studies, it was the quitting method cited by 76%, 85%, or 88% of long-term successful quitters. In a large British study of ex-smokers in the 1980s, before the advent of pharmacotherapy, 53% of the ex-smokers said that it was "not at all difficult" to stop, 27% said it was "fairly difficult", and the remaining 20% found it very difficult. Cold turkey methods have been advanced by J. Wayne McFarland and Elman J. Folkenburg;Joel Spitzer and John R. Polito;Allen Carr, and Jason Wright.
Healthcare provider and systems
Interventions delivered via healthcare providers and healthcare systems have been shown to improve smoking cessation among people who visit those providers.
A clinic screening system (e.g., computer prompts) to identify whether or not a person smokes doubled abstinence rates, from 3.1% to 6.4%.:78–79 Similarly, the Task Force on Community Preventive Services determined that provider reminders alone or with provider education are effective in promoting smoking cessation.:33–38
A 2008 Guideline meta-analysis estimated that physician advice to quit smoking led to a quit rate of 10.2%, as opposed to a quit rate of 7.9% among patients who did not receive physician advice to quit smoking.:82–83 A Cochrane review found that even brief advice from physicians had "a small effect on cessation rates." However, one study from Ireland involving vignettes found that physicians' probability of giving smoking cessation advice declines with the patient's age, and another study from the U.S. found that only 81% of smokers age 50 or greater received advice on quitting from their physicians in the preceding year.
For one-to-one or person-to-person counselling sessions, the duration of each session, the total amount of contact time, and the number of sessions all correlated with the effectiveness of smoking cessation. For example, "Higher intensity" interventions (>10 minutes) produced a quit rate of 22.1% as opposed to 10.9% for "no contact"; over 300 minutes of contact time produced a quit rate of 25.5% as opposed to 11.0% for "no minutes"; and more than 8 sessions produced a quit rate of 24.7% as opposed to 12.4% for 0–1 sessions.:83–86
Both physicians and non-physicians increased abstinence rates compared with self-help or no clinicians.:87–88 For example, a Cochrane review of 31 studies found that nursing interventions increased the likelihood of quitting by 28%.
Dental professionals also provide a key component in increasing tobacco abstinence rates in the community through counseling patients on the effects of tobacco on oral health in conjunction with an oral exam.
According to the 2008 Guideline, based on two studies the training of clinicians in smoking cessation methods may increase abstinence rates:130; however, a Cochrane review found and measured that such training decreased smoking in patients.
Reducing or eliminating the costs of cessation therapies for smokers increased quit rates in three meta-analyses.:139–140:38–40
In one systematic review and meta-analysis, multi-component interventions increased quit rates in primary care settings. "Multi-component" interventions were defined as those that combined two or more of the following strategies known as the "5 A's":38–43:
Ask — Systematically identify all tobacco users at every visit
Advise — Strongly urge all tobacco users to quit
Breath CO monitor displaying carbon monoxide concentration of an exhaled breath sample (in ppm) with its corresponding percent concentration of carboxyhemoglobin.
Assess — Determine willingness to make a quit attempt
Assist — Aid the patient in quitting (provide counselling-style support and medication)
Arrange — Ensure follow-up contact
Various methods exist which allow a smoker to see the impact of their tobacco use, and the immediate effects of quitting. Using biochemical feedback methods can allow tobacco-users to be identified and assessed, and the use of monitoring throughout an effort to quit can increase motivation to quit.
Breath carbon monoxide (CO) monitoring: Because carbon monoxide is a significant component of cigarette smoke, a breath carbon monoxide monitor can be used to detect recent cigarette use. Carbon monoxide concentration in breath has been shown to be directly correlated with the CO concentration in blood, known as percent carboxyhemoglobin. The value of demonstrating blood CO concentration to a smoker through a non-invasive breath sample is that it links the smoking habit with the physiological harm associated with smoking. Within hours of quitting, CO concentrations show a noticeable decrease, and this can be encouraging for someone working to quit. Breath CO monitoring has been utilized in smoking cessation as a tool to provide patients with biomarker feedback, similar to the way in which other diagnostic tools such as the stethoscope, the blood pressure cuff, and the cholesterol test have been used by treatment professionals in medicine.
Cotinine: A metabolite of nicotine, cotinine is present in smokers. Like carbon monoxide, a cotinine test can serve as a reliable biomarker to determine smoking status. Cotinine levels can be tested through urine, saliva, blood, or hair samples, with one of the main concerns of cotinine testing being the invasiveness of typical sampling methods.
While both measures offer high sensitivity and specificity, they differ in usage method and cost. As an example, breath CO monitoring is non-invasive, while cotinine testing relies on a bodily fluid. These two methods can be used either alone or together, for example, in a situation where abstinence verification needs additional confirmation.
A 21mg dose Nicoderm CQ patch applied to the left arm.
The American Cancer Society estimates that "between about 25% and 33% of smokers who use medicines can stay smoke-free for over 6 months." Single medications include:
Nicotine replacement therapy (NRT): Five medications approved by the U.S. Food and Drug Administration (FDA) deliver nicotine in a form that does not involve the risks of smoking. NRTs are meant to be used for a short period of time and should be tapered down to a low dose before stopping. The five NRT medications, which in a Cochrane review increased the chances of stopping smoking by 50 to 70% compared to placebo or to no treatment, are:
transdermal nicotine patches deliver doses of the addictive chemical nicotine, thus reducing the unpleasant effects of nicotine withdrawal. These patches can give smaller and smaller doses of nicotine, slowly reducing dependence upon nicotine and thus tobacco. A Cochrane review found further increased chance of success in a combination of the nicotine patch and a faster acting form. Also, this method becomes most effective when combined with other medication and psychological support.
A study found that 93 percent of over-the-counter NRT users relapse and return to smoking within six months.
Antidepressant: Bupropion is FDA-approved and is marketed under the brand name Zyban. Bupropion is contraindicated in epilepsy, seizure disorder; anorexia/bulimia (eating disorders), patients' use of antidepressant drugs (MAO inhibitors) within 14 days, patients undergoing abrupt discontinuation of ethanol or sedatives (including benzodiazepines such as Valium). Evidence from a systematic review suggests that antidepressants such as Bupropion and Nortriptyline help in long-term smoking cessation and that adverse events with both drugs are rarely serious enough to cause stopping of the medication. The evidence also points out that Bupropion is less effective than Varenicline however this needs to be further validated.
Cytisine (Tabex) is a plant extract that has been in use since the 1960s in former Soviet-bloc countries. It was the first medication approved as an aid to smoking cessation, and has very few side effects in small doses.:70
Varenicline tartrate is a prescription drug marketed by Pfizer as Chantix in the U.S. (under FDA approval) and as Champix outside the U.S. Synthesized as an improvement upon cytisine, varenicline decreases the urge to smoke and reduces withdrawal symptoms. Two systematic reviews and meta-analyses supported by unrestricted funding from Pfizer, one in 2006 and one in 2009, found varenicline more effective than NRT or bupropion. A table in the 2008 Guideline indicates that 2 mg/day of varenicline leads to the highest abstinence rate (33.2%) of any single therapy, while 1 mg/day leads to an abstinence rate of 25.4%.:109 A 2011 Cochrane review of 15 studies (13 of which had been sponsored by Pfizer) found that varenicline was significantly superior to bupropion at one year but that varenicline and nicotine patches produced the same level of abstinence at 24 weeks. A 2011 review of double-blind studies found that varenicline has increased risk of serious adverse cardiovascular events compared with placebo. Varenicline may cause neuropsychiatric side effects; for example, in 2008 the UK. Medicines and Healthcare products Regulatory Agency issued a warning about possible suicidal thoughts and suicidal behavior associated with varenicline.
Moclobemide has been tested in heavy dependent smokers against placebo based on the theory that tobacco smoking could be a form of self medicating of major depression, and moclobemide could therefore help increase abstinence rates due to moclobemide mimicking the MAO-A inhibiting effects of tobacco smoke. Moclobemide was administered for 3 months and then stopped; at 6 months follow-up it was found those who had taken moclobemide for 3 months had a much higher successful quit rate than those in the placebo group. However, at 12 month follow-up the difference between the placebo group and the moclobemide group was no longer significant.
Two other medications have been used in trials for smoking cessation, although they are not approved by the FDA for this purpose. They may be used under careful physician supervision if the first line medications are contraindicated for the patient.
Clonidine may reduce withdrawal symptoms and "approximately doubles abstinence rates when compared to a placebo," but its side effects include dry mouth and sedation, and abruptly stopping the drug can cause high blood pressure and other side effects.:55,116–117
Nortriptyline, another antidepressant, has similar success rates to bupropion but has side effects including dry mouth and sedation.:56,117–118
Combinations of medications
The 2008 US Guideline specifies that three combinations of medications are effective:118–120:
Long-term nicotine patch and ad libitum NRT gum or spray
Nicotine patch and nicotine inhaler
Nicotine patch and bupropion (the only combination that the US FDA has approved for smoking cessation)
Cut down to quit
Gradual reduction involves slowly reducing one's daily intake of nicotine. This can theoretically be accomplished through repeated changes to cigarettes with lower levels of nicotine, by gradually reducing the number of cigarettes smoked each day, or by smoking only a fraction of a cigarette on each occasion. A 2009 systematic review by researchers at the University of Birmingham found that gradual nicotine replacement therapy could be effective in smoking cessation. A 2010 Cochrane review found that abrupt cessation and gradual reduction with pre-quit NRT produced similar quit rates whether or not pharmacotherapy or psychological support was used.  According to a more recent 2012 Cochranesystematic review analysis of 10 studies and 3670 patients, overall relative risk reduction between smokers who attempted to quit with abrupt cessation or with gradual reduction techniques was 0.06. This analysis demonstrated that there was no significant difference in quit rates between smokers who quit by gradual reduction or abrupt cessation as measured by abstinence from smoking of at least six months from the quit day, suggesting that patients who want to quit can choose between these two methods.
A Cochrane review found evidence that community interventions using "multiple channels to provide reinforcement, support and norms for not smoking" had an effect on smoking cessation outcomes among adults. Specific methods used in the community to encourage smoking cessation among adults include:
Policies making workplaces and public places smoke-free. It is estimated that "comprehensive clean indoor laws" can increase smoking cessation rates by 12%–38%. In 2008, the New York State of Alcoholism and Substantance Abuse Services banned smoking by patients, staff and volunteers at 1,300 addiction treatment centers.
Voluntary rules making homes smoke-free, which are thought to promote smoking cessation.
Increasing the price of tobacco products, for example by taxation. The US Task Force on Community Preventive Services found "strong scientific evidence" that this is effective in increasing tobacco use cessation.:28–30 It is estimated that an increase in price of 10% will increase smoking cessation rates by 3–5%.
Mass media campaigns. The US Task Force on Community Preventive Services declared that "strong scientific evidence" existed for these when "combined with other interventions":30–32, but a Cochrane review concluded that it was "difficult to establish their independent role and value".
Competitions and incentives
One 2008 Cochrane review concluded that "incentives and competitions have not been shown to enhance long-term cessation rates." However, a trial published in 2009 found that financial incentives for smoking cessation led to significantly higher rates of smoking cessation 15–18 months after enrollment. Furthermore, a different 2008 Cochrane review found that one type of competition, "Quit and Win," did increase quit rates among participants.
Great American Smokeout is an annual event that invites smokers to quit for one day, hoping they will be able to extend this forever.
Smoking-cessation support is often offered over the internet, over the telephone quitlines (e.g., the US toll-free number 1-800-QUIT-NOW), or in person. Three meta-analyses have concluded that telephone cessation support is effective when compared with minimal or no counselling or self-help, and that telephone cessation support with medication is more effective than medication alone.:91–92:40–42
The Freedom From Smoking group clinic includes eight sessions and features a step-by-step plan for quitting smoking. Each session is designed to help smokers gain control over their behavior. The clinic format encourages participants to work on the process and problems of quitting both individually and as part of a group
Multiple formats of psychosocial interventions increase quit rates: 10.8% for no intervention, 15.1% for one format, 18.5% for 2 formats, and 23.2% for three or four formats.:91
The Transtheoretical Model including "stages of change" has been used in tailoring smoking cessation methods to individuals. However, a 2010 Cochrane review concluded that "stage-based self-help interventions (expert systems and/or tailored materials) and individual counselling were neither more nor less effective than their non-stage-based equivalents."
Some health organizations manage text messaging services to help people avoid smoking
A 2005 Cochrane review found that self-help materials may produce only a small increase in quit rates. In the 2008 Guideline, "the effect of self-help was weak," and the number of types of self-help did not produce higher abstinence rates.:89–91 Nevertheless, self-help modalities for smoking cessation include:
Interactive web-based and stand-alone computer programs and online communities which assist participants in quitting, such as EX and QuitNet. For example, "quit meters" keep track of statistics such as how long a person has remained abstinent. In the 2008 US Guideline, there was no meta-analysis of computerised interventions, but they were described as "highly promising.":93–94 A meta-analysis published in 2009, a Cochrane review published in 2010, and a 2011 systematic review found the evidence base for such interventions weak.
Mobile phone-based interventions: A 2009 Cochrane review stated that "more evidence is needed" to determine the effectiveness of such interventions. As of 2009, a randomised trial of mobile phone-based smoking cessation support was underway in the UK.
Spirituality: In one survey of adult smokers, 88% reported a history of spiritual practice or belief, and of those more than three-quarters were of the opinion that using spiritual resources may help them quit smoking.
Substitutes for cigarettes
Electronic cigarette: Shaped like a cigarette to emulate the tactile experience of smoking, electronic cigarettes contain a rechargeable battery and a heating element which vaporises liquid nicotine and other flavorings from an insertable cartridge. Proponents of electronic cigarettes often market them as a smoking cessation device. Many claim that electronic cigarettes deliver the experience of smoking without the adverse health effects usually associated with tobacco smoke, or at least greatly reduce those risks. However, in September 2008, the World Health Organization issued a release proclaiming that it does not consider the electronic cigarette to be a legitimate smoking cessation aid, stating that "no rigorous, peer-reviewed studies have been conducted showing that the electronic cigarette is a safe and effective nicotine replacement therapy."
The US National Institute of Health recommends chewing cinnamon sticks when trying to quit the use of tobacco. In addition to raw cinnamon sticks, cinnamon-flavoured toothpicks are used to help curb the urge for tobacco.
Plastic cigarette substitute: In one 2006 study, giving people a free "Better Quit" hollow tube resembling a cigarette did not improve quit rates.
Acupuncture: Acupuncture has been explored as an adjunct treatment method for smoking cessation. A Cochrane review concluded that acupuncture "do[es] not appear to help smokers who are trying to quit", a meta-analysis from the 2008 Guideline showed no difference between acupuncture and placebo,:99–100 and the 2008 Guideline found no scientific studies supporting laser therapy based on acupuncture principles but without the needles.:99
Aromatherapy: A 2006 book reviewing the scientific literature on aromatherapy identified only one study on smoking cessation and aromatherapy; the study found that "inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms".
Hypnosis: Hypnosis often involves the hypnotherapist suggesting to the patient the unpleasant outcomes of smoking. Clinical trials studying hypnosis and hypnotherapy as a method for smoking cessation have been inconclusive:100; however, a randomized trial published in 2008 found that hypnosis and nicotine patches "compares favorably" with standard behavioral counseling and nicotine patches in 12-month quit rates.
Herbs: Many herbs have been studied as a method for smoking cessation, including lobelia and St John's wort. The results are inconclusive, but St. Johns Wort shows few adverse events. Lobelia has been used to treat respiratory diseases like asthma and bronchitis, and has been used for smoking cessation because of chemical similarities to tobacco; lobelia is now listed in the FDA's Poisonous Plant Database. Lobelia can still be found in many products sold for smoking cessation and should be used with caution.
Smokeless tobacco: There is little smoking in Sweden, which is reflected in the very low cancer rates for Swedish men. Use of snus (a form of steam-pasteurised, rather than heat-pasteurised, air-cured smokeless tobacco) is an observed cessation method for Swedish men and even recommended by some Swedish doctors.
There are many other measures used in an effort to quit smoking which lack evidence including: a substance put on the cigarette called NicoBloc. Due to the lack of evidence they are typically not recommended.
Children and adolescents
Methods used with children and adolescents include:
A Cochrane review, mainly of studies combining motivational enhancement and psychological support, concluded that "complex approaches" for smoking cessation among young people show promise. The 2008 US Guideline recommends counselling-style support for adolescent smokers on the basis of a meta-analysis of seven studies.:159–161 Neither the Cochrane review nor the 2008 Guideline recommends medications for adolescents who smoke.
Smoking during pregnancy can cause adverse health effects in both the woman and the fetus. The 2008 US Guideline determined that "person-to-person psychosocial interventions" (typically including "intensive counseling") increased abstinence rates in pregnant women who smoke to 13.3%, compared with 7.6% in usual care.:165–167 Mothers who smoke during pregnancy have a greater tendency towards premature births. Their babies are often underdeveloped, have smaller organs, and weigh much less compared with the normal baby. In addition, these babies have worse immune systems, making them more susceptible to many diseases in early childhood, such as middle ear inflammations and asthmatic bronchitis which can bring about a lot of agony and suffering. As well, there is a high chance that they will become smokers themselves when grown up.
It is a widely spread myth that a female smoker can cause harm to her fetus by quitting immediately upon discovering that she is with child. Though this idea does seem to follow logic, it is not based on any medical study or fact.
A 2008 Cochrane review of smoking cessation activities in work-places concluded that "interventions directed towards individual smokers increase the likelihood of quitting smoking." A 2010 systematic review determined that worksite incentives and competitions needed to be combined with additional interventions to produce significant increases in smoking cessation rates.
Percent increase of success for six months over unaided attempts for each type of quitting (chart from West & Shiffman based on Cochrane review data:59
Smokers who are hospitalised may be particularly motivated to quit.:149–150 A 2007 Cochrane review found that interventions beginning during a hospital stay and continuing for one month or more after discharge were effective in producing abstinence.
Comparison of success rates
Comparison of success rates across interventions can be difficult because of different definitions of "success" across studies. Robert West and Saul Shiffman, authorities in this field recognised by government health departments in a number of countries :73,76,80, have concluded that, used together, "behavioural support" and "medication" can quadruple the chances that a quit attempt will be successful.
A 2008 systematic review in the European Journal of Cancer Prevention found that group behavioural therapy was the most effective intervention strategy for smoking cessation, followed by bupropion, intensive physician advice, nicotine replacement therapy, individual counselling, telephone counselling, nursing interventions, and tailored self-help interventions; the study did not discuss varenicline.
Individuals who sustained damage to the insula were able to more easily abstain from smoking.
Factors affecting success
Quitting can be harder for individuals with dark pigmented skin compared to individuals with pale skin since nicotine has an affinity for melanin-containing tissues. Studies suggest this can cause the phenomenon of increased nicotine dependence and lower smoking cessation rate in darker pigmented individuals.
There is an important social component to smoking. A 2008 study of a densely interconnected network of over 12,000 individuals found that smoking cessation by any given individual reduced the chances of others around them lighting up by the following amounts: a spouse by 67%, a sibling by 25%, a friend by 36%, and a coworker by 34%. Nevertheless, a Cochrane review determined that interventions to increase social support for a smoker's cessation attempt did not increase long-term quit rates.
Smokers who are trying to quit are faced with social influences that may persuade them to conform and continue smoking. Cravings are easier to detain when one's environment does not provoke the habit. If a person who stopped smoking has close relationships with active smokers they are often put into situations that make the urge to conform more tempting. However, in a small group with at least one other not smoking, the likelihood of conformity decreases. The social influence to smoke cigarettes has been proven to rely on simple variables. One researched variable depends on whether the influence is from a friend or non-friend. the research shows that individuals are 77% more likely to conform to non-friends, while close friendships decrease conformity. Therefore, if an acquaintance offers a cigarette as a polite gesture, the person who has stopped smoking will be more likely to break his commitment than if a friend had offered.
Relapse (resuming smoking after quitting) has been related to psychological issues such as low self-efficacy or non-optimal coping responses; however, psychological approaches to prevent relapse have not been proven to be successful. In contrast, varenicline may help some relapsed smokers.
In a 2007 review of the effects of abstinence from tobacco, Hughes concluded that "anger, anxiety, depression, difficulty concentrating, impatience, insomnia, and restlessness are valid withdrawal symptoms that peak within the first week and last 2–4 weeks." In contrast, "constipation, cough, dizziness, increased dreaming, and mouth ulcers" may or may not be symptoms of withdrawal, while drowsiness, fatigue, and certain physical symptoms ("dry mouth, flu symptoms, headaches, heart racing, skin rash, sweating, tremor") were not symptoms of withdrawal.
Giving up smoking is associated with an average weight gain of 4–5 kilograms (8.8–11.0 lb) after 12 months, most of which occurs within the first three months of quitting.
The possible causes of the weight gain include:
Smoking over-expresses the gene AZGP1 which stimulates lipolysis, so smoking cessation may decrease lipolysis.
Heavy smokers are reported to burn 200 calories per day more than non-smokers eating the same diet. Possible reasons for this phenomenon include nicotine's ability to increase energy metabolism or nicotine's effect on peripheral neurons.
The 2008 Guideline suggests that sustained-release bupropion, nicotine gum, and nicotine lozenge be used "to delay weight gain after quitting.":173–176 However, a 2012 Cochrane review concluded that "The data are not sufficient to make strong clinical recommendations for effective programmes" for preventing weight gain.
Like other physically addictive drugs, nicotine withdrawal causes down-regulation of the production of dopamine and other stimulatory neurotransmitters as the brain attempts to compensate for artificial stimulation. Therefore, when people stop smoking, depressive symptoms such as suicidal tendencies or actual depression may result. This side effect of smoking cessation may be particularly common in women, as depression is more common among women than among men.
A recent study by The British Journal of Psychiatry has found that smokers who successfully quit feel less anxious afterwards with the effect being greater among those who had mood and anxiety disorders than those that smoked for pleasure.
Many of tobacco's detrimental health effects can be reduced or largely removed through smoking cessation. The health benefits over time of stopping smoking include:
Within 5 years, the risk of stroke falls to the same as a non-smoker, and the risks of many cancers (mouth, throat, esophagus, bladder, cervix) decrease significantly
Within 10 years, the risk of dying from lung cancer is cut in half, and the risks of larynx and pancreas cancers decrease
Within 15 years, the risk of coronary heart disease drops to the level of a non-smoker; lowered risk for developing COPD (chronic obstructive pulmonary disease)
The British doctors study showed that those who stopped smoking before they reached 30 years of age lived almost as long as those who never smoked. Stopping in one's sixties can still add three years of healthy life. A randomized trial from the U.S. and Canada showed that a smoking cessation program lasting 10 weeks decreased mortality from all causes over 14 years later.
Another published study, "Smoking Cessation Reduces Postoperative Complications: A Systematic Review and Meta-analysis," examined six randomized trials and 15 observational studies to look at the effects of preoperative smoking cessation on postoperative complications. The findings were: 1) taken together, the studies demonstrated decreased likelihood of postoperative complications in patients who ceased smoking prior to surgery; 2) overall, each week of cessation prior to surgery increased the magnitude of the effect by 19%. A significant positive effect was noted in trials where smoking cessation occurred at least four weeks prior to surgery; 3) For the six randomized trials, they demonstrated on average a relative risk reduction of 41% for postoperative complications.
Smokers as a percentage of the population for the United States, the Netherlands, Norway, Japan, and Finland.
In a 1997 U.S. analysis, the estimated cost per QALY varied by the type of cessation approach, ranging from group intensive counselling without nicotine replacement at $1108 per QALY to minimal counselling with nicotine gum at $4542 per QALY.
Among National Health Service smoking cessation clients in Glasgow, pharmacy one-to-one counselling cost £2,600 per QALY gained and group support cost £4,800 per QALY gained.
The frequency of smoking cessation among smokers varies across countries. Smoking cessation increased in Spain between 1965 and 2000, in Scotland between 1998 and 2007, and in Italy after 2000. In contrast, in the U.S. the cessation rate was "stable (or varied little)" between 1998 and 2008, and in China smoking cessation rates declined between 1998 and 2003.
Nevertheless, in a growing number of countries there are now more ex-smokers than smokers. For example, in the U.S. as of 2010, there were 47 million ex-smokers and 46 million smokers.
^Fiore MC, Bailey WC, Cohen SJ, et al (1996). Smoking cessation. Clinical practice guideline no. 18. AHCPR publication no. 96-0692. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.
^ abcFiore MC, Novotny TE, Pierce JP, Giovino GA, Hatziandreu EJ, Newcomb PA, Surawicz TS, Davis RM (1990). "Methods used to quit smoking in the United States. Do cessation programs help?". JAMA263 (20): 2760–5. doi:10.1001/jama.263.20.2760. PMID2271019.
^Doran CM, Valenti L, Robinson M, Britt H, Mattick RP (2006). "Smoking status of Australian general practice patients and their attempts to quit". Addict Behav31 (5): 758–66. doi:10.1016/j.addbeh.2005.05.054. PMID16137834.
^Maguire CP, Ryan J, Kelly A, O'Neill D, Coakley D, Walsh JB (2000). "Do patient age and medical condition influence medical advice to stop smoking?". Age Ageing29 (3): 264–6. doi:10.1093/ageing/29.3.264. PMID10855911.
^Reda AA, Kaper J, Fikrelter H, Severens JL, van Schayck CP (2009). "Healthcare financing systems for increasing the use of tobacco dependence treatment". In Van Schayck, Constant Paul. Cochrane Database Syst Rev (2): CD004305. doi:10.1002/14651858.CD004305.pub3. PMID19370599.
^Papadakis S, McDonald P, Mullen KA, Reid R, Skulsky K, Pipe A (2010). "Strategies to increase the delivery of smoking cessation treatments in primary care settings: a systematic review and meta-analysis". Prev Med51 (3–4): 199–213. doi:10.1016/j.ypmed.2010.06.007. PMID20600264.
^ abBittoun R. (2008). Carbon monoxide meter: The essential clinical tool- the ‘stethoscope"-of smoking cessation. Journal of Smoking Cessation, 3(2); 69-70.
^Jamrozik K, Vessey M, Fowler G, Nicholas W, Parker G, and van Vunakis H. (1984). Controlled trial of three different anti-smoking interventions in general practice. British Medical Journal, 288; 1499-1503.
^Irving JM, Clark EC, Crombie IK, and Smith WC. (1988). Evaluation of a portable measure of expired-air carbon monoxide. Preventive Medicine, 17; 109-115.
^Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G (February 2009). "Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology". Therapeutic Drug Monitoring 31 (1): 14–30. .doi:10.1097/FTD.0b013e3181957a3bPMID 19125149.
^5. McClure JB. (2002). Are biomarkers useful treatment aids for promoting health behavior change? American Journal of Preventive Medicine, 22 (3); 200-207.
^Lindson-Hawley N, Aveyard P, Hughes JR (2012). "Reduction versus abrupt cessation in smokers who want to quit". In Lindson-Hawley, Nicola. Cochrane Database of Systematic Reviews11 (11): CD008033. doi:10.1002/14651858.CD008033.pub3. PMID23152252.
^Secker-Walker RH, Gnich W, Platt S, Lancaster T (2002). "Community interventions for reducing smoking among adults". In Stead, Lindsay F. Cochrane Database Syst Rev (3): CD001745. doi:10.1002/14651858.CD001745. PMID12137631.
^Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, Galvin R, Zhu J, Wan F, DeGuzman J, Corbett E, Weiner J, Audrain-McGovern J (2009). "A randomized, controlled trial of financial incentives for smoking cessation". N Engl J Med360 (7): 699–709. doi:10.1056/NEJMsa0806819. PMID19213683.
^Zhu SH, Anderson CM, Tedeschi GJ, Rosbrook B, Johnson CE, Byrd M, Gutiérrez-Terrell E (2002). "Evidence of real-world effectiveness of a telephone quitline for smokers". N Engl J Med347 (14): 1087–93. doi:10.1056/NEJMsa020660. PMID12362011.
^Hutton HE, Wilson LM, Apelberg BJ, Avila Tang E, Odelola O, Bass EB, Chander G (Feb 2011). "A systematic review of randomized controlled trials: web-based interventions for smoking cessation among adolescents, college students, and adults". Nicotine Tob Res13 (4): 227–38. doi:10.1093/ntr/ntq252. PMID21350042.
^Whittaker R, Borland R, Bullen C, Lin RB, McRobbie H, Rodgers A (2009). "Mobile phone-based interventions for smoking cessation". In Whittaker, Robyn. Cochrane Database Syst Rev (4): CD006611. doi:10.1002/14651858.CD006611.pub2. PMID19821377.
^Free C, Whittaker R, Knight R, Abramsky T, Rodgers A, Roberts IG (2009). "Txt2stop: a pilot randomised controlled trial of mobile phone-based smoking cessation support". Tob Control18 (2): 88–91. doi:10.1136/tc.2008.026146. PMID19318534.
^Gonzales D, Redtomahawk D, Pizacani B, Bjornson WG, Spradley J, Allen E, Lees P (2007). "Support for spirituality in smoking cessation: results of pilot survey". Nicotine Tob Res9 (2): 299–303. doi:10.1080/14622200601078582. PMID17365761.
^He, Dong; Berg, John E.; Høstmark, Arne T. (March 1997). "Effects of acupuncture on smoking cessation or reduction for motivated smokers". Preventive Medicine26 (2): 208–214. doi:10.1006/pmed.1996.0125. PMID9085389.
^White AR, Rampes H, Liu JP, Stead LF, Campbell J (2011). "Acupuncture and related interventions for smoking cessation". In White, Adrian R. Cochrane Database Syst Rev (1): CD000009. doi:10.1002/14651858.CD000009.pub3. PMID21249644.
^Lis-Balchin M (2006). Aromatherapy science: a guide for healthcare professionals. London: Pharmaceutical Press. p. 101. ISBN0-85369-578-4.
^Johnson, D.L.; Karkut, R.T. (October 1994). "Performance by gender in a stop-smoking program combining hypnosis and aversion". Psychological reports75 (2): 851–7. doi:10.2466/pr0.19188.8.131.521. PMID7862796.
^McRobbie, H; Bullen, C; Glover, M; Whittaker, R; Wallace-Bell, M; Fraser, T; New Zealand Guidelines, Group (Jun 20, 2008). "New Zealand smoking cessation guidelines". The New Zealand medical journal121 (1276): 57–70. PMID18574510.
^Park EW, Schultz JK, Tudiver F, Campbell T, Becker L (2004). "Enhancing partner support to improve smoking cessation". In Park, Eal Whan. Cochrane Database Syst Rev (3): CD002928. doi:10.1002/14651858.CD002928.pub2. PMID15266469.
^Peoples, Clayton D.; Sigillo, Alexandra E.; Green, Morgan; Miller, Monica K. (2012). "Friendship and Conformity in Group Opinions: Juror Verdict Change in Mock Juries". Sociological Spectrum32 (2): 178. doi:10.1080/02732173.2012.646163.
^H.-J. Aubin, A. Farley, D. Lycett, P. Lahmek, P. Aveyard. (2012). "Weight gain in smokers after quitting cigarettes: meta-analysis". BMJ-British Medical Journal345 (345): e4439. doi:10.1136/bmj.e4439.
^Covey LS, Glassman AH, Stetner F (1997). "Major depression following smoking cessation". Am J Psychiatry154 (2): 263–5. PMID9016279.
^Borrelli B, Bock B, King T, Pinto B, Marcus BH (1996). "The impact of depression on smoking cessation in women". Am J Prev Med12 (5): 378–87. PMID8909649.
^Máirtín S. McDermott, Theresa M. Marteau, Gareth J. Hollands, Matthew Hankins and Paul Aveyard. "Change in anxiety following successful and unsuccessful attempts at smoking cessation: cohort study". BJP.
^Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group (2005). "The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial". Annals of Internal Medicine142 (4): 233–9. doi:10.7326/0003-4819-142-4-200502150-00005. PMID15710956.
^Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T (1997). "Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation". JAMA278 (21): 1759–66. doi:10.1001/jama.278.21.1759. PMID9388153.
^Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Mölken MP (2010). "Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD". Thorax65 (8): 711–8. doi:10.1136/thx.2009.131631. PMID20685746.
^Bauld L, Boyd KA, Briggs AH, Chesterman J, Ferguson J, Judge K, Hiscock R (2011). "One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services". Nicotine Tob Res13 (2): 135–45. doi:10.1093/ntr/ntq222. PMID21196451.
^Schiaffino A, Fernández E, Kunst A, Borrell C, García M, Borràs JM, Mackenbach JP (2007). "Time trends and educational differences in the incidence of quitting smoking in Spain (1965–2000)". Prev Med45 (2–3): 226–32. doi:10.1016/j.ypmed.2007.05.009. PMID17604832.
Hutter H, Moshammer H, Neuberger M (2006). "Smoking cessation at the workplace: 1 year success of short seminars". Int Arch Occup Environ Health79 (1): 42–8. doi:10.1007/s00420-005-0034-y. PMID16133522.
Marks DF (2005). Overcoming your smoking habit: a self-help guide using cognitive behavioral techniques. London: Robinson. ISBN1-84529-067-4.